HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A sphingosine-1-phosphate receptor type 1 agonist, ASP4058, suppresses intracranial aneurysm through promoting endothelial integrity and blocking macrophage transmigration.

AbstractBACKGROUND AND PURPOSE:
Intracranial aneurysm (IA), common in the general public, causes lethal subarachnoid haemorrhage on rupture. It is, therefore, of utmost importance to prevent the IA from rupturing. However, there is currently no medical treatment. Recent studies suggest that IA is the result of chronic inflammation in the arterial wall caused by endothelial dysfunction and infiltrating macrophages. The sphingosine-1-phosphate receptor type 1 (S1P1 receptor) is present on the endothelium and promotes its barrier function. Here we have tested the potential of an S1P1 agonist, ASP4058, to prevent IA in an animal model.
EXPERIMENTAL APPROACH:
The effects of a selective S1P1 agonist, ASP4058, on endothelial permeability and migration of macrophages across an endothelial cell monolayer were tested in vitro using a Transwell system, and its effects on the size of IAs were evaluated in a rat model of IA.
KEY RESULTS:
S1P1 receptor was expressed in endothelial cells of human IA lesions and control arterial walls. ASP4058 significantly reduced FITC-dextran leakage through an endothelial monolayer and suppressed the migration of macrophages across the monolayer in vitro. Oral administration of ASP4058 reduced the vascular permeability, macrophage infiltration and size of the IAs by acting as an S1P1 agonist in the rat model. This effect was mimicked by another two structurally-unrelated S1P1 agonists.
CONCLUSION AND IMPLICATIONS:
A selective S1P1 agonist is a strong drug candidate for IA treatment as it promotes the endothelial cell barrier and suppresses the trans-endothelial migration of macrophages in IA lesions.
AuthorsRie Yamamoto, Tomohiro Aoki, Hirokazu Koseki, Miyuki Fukuda, Jun Hirose, Keiichi Tsuji, Katsumi Takizawa, Shinichiro Nakamura, Haruka Miyata, Nozomu Hamakawa, Hidetoshi Kasuya, Kazuhiko Nozaki, Yoshitaka Hirayama, Ichiro Aramori, Shuh Narumiya
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 174 Issue 13 Pg. 2085-2101 (07 2017) ISSN: 1476-5381 [Electronic] England
PMID28409823 (Publication Type: Journal Article)
Copyright© 2017 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Chemical References
  • ASP4058
  • Benzimidazoles
  • Oxadiazoles
  • Receptors, Lysosphingolipid
  • S1PR1 protein, human
  • Sphingosine-1-Phosphate Receptors
Topics
  • Benzimidazoles (pharmacology)
  • Capillary Permeability (drug effects)
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Endothelial Cells (drug effects, metabolism)
  • Humans
  • Intracranial Aneurysm (drug therapy, metabolism, pathology)
  • Macrophages (cytology, drug effects)
  • Oxadiazoles (pharmacology)
  • Receptors, Lysosphingolipid (agonists, genetics, metabolism)
  • Sphingosine-1-Phosphate Receptors
  • Structure-Activity Relationship
  • Transendothelial and Transepithelial Migration (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: